If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Upcoming IPO
Vistas Media Acquisition (VMACU)
ARYA Sciences Acquisition III (ARYA)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

I-Mab (IMAB)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. They were founded to capture the opportunities presented by the confluence of two major developments: the emergence of an attractive and growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. They believe they are well-positioned to become a biotech leader in China because of their innovative discovery expertise, fit-for-purpose technology platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further enhanced by their deep understanding of China’s biologics regulatory framework and their direct access to extensive pre-clinical and clinical trial resources in China. To date, they have developed an innovative pipeline of more than 10 clinical and pre-clinical stage assets through their internal research and development efforts and in-licensing arrangements with global pharmaceutical and biotech companies.
Joan Huaqiong Shen Jielun Zhu
Employees Founded
185 2014


Address: Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, People’s Republic of China

Telephone: +86 21-6057-8000.

Web page:

IPO information

Expected Date 1/17/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $778.3
Revenues (MM) $6.7
Net Income (Loss) (MM) $-146.8


What do you think will happen with the IMAB share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 7.4
Shares Revised (MM) 7.4
Expected offer amount (MM) $100
Realized offer amount(MM) $103.6
Jefferies/ CICC
China Renaissance/ Huatai Securities (USA)

Sector: Healthcare

Tweets about $IMAB

Tweets volume:

RT volume:


Google Trends Stats